CN110840886A - 抗生素呋喃妥因（Nitrofurantoi）可作为新型抗心律失常药物 - Google Patents
抗生素呋喃妥因（Nitrofurantoi）可作为新型抗心律失常药物 Download PDFInfo
- Publication number
- CN110840886A CN110840886A CN201810946685.7A CN201810946685A CN110840886A CN 110840886 A CN110840886 A CN 110840886A CN 201810946685 A CN201810946685 A CN 201810946685A CN 110840886 A CN110840886 A CN 110840886A
- Authority
- CN
- China
- Prior art keywords
- nitrofurantoin
- arrhythmia
- potential
- nitrofuratoi
- zacopride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960000564 nitrofurantoin Drugs 0.000 title claims abstract description 21
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 title claims abstract description 21
- 239000003416 antiarrhythmic agent Substances 0.000 title description 14
- 230000003115 biocidal effect Effects 0.000 title description 3
- 239000003814 drug Substances 0.000 claims abstract description 29
- 206010003119 arrhythmia Diseases 0.000 claims abstract description 28
- 230000006793 arrhythmia Effects 0.000 claims abstract description 24
- 239000007788 liquid Substances 0.000 claims description 10
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 3
- 239000002876 beta blocker Substances 0.000 claims description 3
- 239000000480 calcium channel blocker Substances 0.000 claims description 3
- 239000003195 sodium channel blocking agent Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 239000003094 microcapsule Substances 0.000 claims description 2
- 229940125422 potassium channel blocker Drugs 0.000 claims description 2
- 239000003450 potassium channel blocker Substances 0.000 claims description 2
- 229940125794 sodium channel blocker Drugs 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- FEROPKNOYKURCJ-UHFFFAOYSA-N 4-amino-N-(1-azabicyclo[2.2.2]octan-3-yl)-5-chloro-2-methoxybenzamide Chemical compound COC1=CC(N)=C(Cl)C=C1C(=O)NC1C(CC2)CCN2C1 FEROPKNOYKURCJ-UHFFFAOYSA-N 0.000 abstract description 15
- 229950004681 zacopride Drugs 0.000 abstract description 15
- 239000000556 agonist Substances 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 11
- 238000011282 treatment Methods 0.000 abstract description 6
- 230000003288 anthiarrhythmic effect Effects 0.000 abstract description 5
- 230000036982 action potential Effects 0.000 description 25
- 229940079593 drug Drugs 0.000 description 15
- 239000012528 membrane Substances 0.000 description 13
- 230000000284 resting effect Effects 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 108010052164 Sodium Channels Proteins 0.000 description 7
- 102000018674 Sodium Channels Human genes 0.000 description 7
- 210000004165 myocardium Anatomy 0.000 description 7
- 230000010412 perfusion Effects 0.000 description 7
- 102000004310 Ion Channels Human genes 0.000 description 6
- 108090000862 Ion Channels Proteins 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 230000000302 ischemic effect Effects 0.000 description 6
- 230000002107 myocardial effect Effects 0.000 description 6
- 208000010125 myocardial infarction Diseases 0.000 description 5
- 208000031225 myocardial ischemia Diseases 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000002336 repolarization Effects 0.000 description 5
- 206010001497 Agitation Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 210000005240 left ventricle Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 210000001567 regular cardiac muscle cell of ventricle Anatomy 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 3
- 230000003126 arrythmogenic effect Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 230000037024 effective refractory period Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000028161 membrane depolarization Effects 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 108050009340 Endothelin Proteins 0.000 description 2
- 102000002045 Endothelin Human genes 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 206010049447 Tachyarrhythmia Diseases 0.000 description 2
- 208000001871 Tachycardia Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002102 hyperpolarization Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 208000004731 long QT syndrome Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- VLPIATFUUWWMKC-SNVBAGLBSA-N (2r)-1-(2,6-dimethylphenoxy)propan-2-amine Chemical compound C[C@@H](N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-SNVBAGLBSA-N 0.000 description 1
- BUJAGSGYPOAWEI-SECBINFHSA-N (2r)-2-amino-n-(2,6-dimethylphenyl)propanamide Chemical compound C[C@@H](N)C(=O)NC1=C(C)C=CC=C1C BUJAGSGYPOAWEI-SECBINFHSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 206010003662 Atrial flutter Diseases 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- DJBNUMBKLMJRSA-UHFFFAOYSA-N Flecainide Chemical compound FC(F)(F)COC1=CC=C(OCC(F)(F)F)C(C(=O)NCC2NCCCC2)=C1 DJBNUMBKLMJRSA-UHFFFAOYSA-N 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102000009855 Inwardly Rectifying Potassium Channels Human genes 0.000 description 1
- 108010009983 Inwardly Rectifying Potassium Channels Proteins 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 206010042600 Supraventricular arrhythmias Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- IYIKLHRQXLHMJQ-UHFFFAOYSA-N amiodarone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCCN(CC)CC)C(I)=C1 IYIKLHRQXLHMJQ-UHFFFAOYSA-N 0.000 description 1
- 229960005260 amiodarone Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002999 depolarising effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000005584 early death Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960000449 flecainide Drugs 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000001121 heart beat frequency Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229960003404 mexiletine Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960002790 phenytoin sodium Drugs 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 229960000244 procainamide Drugs 0.000 description 1
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229960000203 propafenone Drugs 0.000 description 1
- JWHAUXFOSRPERK-UHFFFAOYSA-N propafenone Chemical compound CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1 JWHAUXFOSRPERK-UHFFFAOYSA-N 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 210000003742 purkinje fiber Anatomy 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000036390 resting membrane potential Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- FJPYVLNWWICYDW-UHFFFAOYSA-M sodium;5,5-diphenylimidazolidin-1-ide-2,4-dione Chemical compound [Na+].O=C1[N-]C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 FJPYVLNWWICYDW-UHFFFAOYSA-M 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960002872 tocainide Drugs 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 208000003663 ventricular fibrillation Diseases 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Abstract
本发明公开了呋喃妥因在制备治疗心律失常药物中的应用。本发明首次发现呋喃妥因能够有效的作为IK1特异性激动剂，其具有和zacopride相类似的效果，可以作为制备抗心律失常作用的药物，因而提供了一条有效、安全治疗的新途径。
Description
技术领域
本发明涉及一种心血管疾病药物，具体而言，涉及呋喃妥因在制备治疗心律失常药物中的应用。
背景技术
心律失常是指心跳频率和节律的异常，严重心律失常往往是心血管疾病患者的主要死因之一。形成严重心律失常的机制很复杂，往往不是单一的机制，但是究其根本，都有心肌离子通道功能活动的改变，由此引起离子流的变化会影响动作电位的发生和形态。那些能够改变动作电位的药物因而可能具有致心律失常风险或抗心律失常的作用。
目前临床应用的抗心律失常药物几乎全部是各种离子通道阻断剂，其主要靶点作用于Na . Kv , Ca 离子通道上，根据药物对离子通道和受体的作用，将治疗快速型心律失常药物分成四类：
Ⅰ类：钠通道阻滞药
Ⅰa：中等强度（适度阻滞钠通道），奎尼丁、普鲁卡因胺
Ⅰb：轻度阻滞钠通道，利多卡因、苯妥英钠、美西律、妥卡尼
Ⅰc：重度阻滞钠通道，普罗帕酮、氟卡尼
此类药物可使阻断钠通道，改变单向组织区的传导，消除折返。
Ⅱ类：β受体阻断药，如普萘洛尔，此类药物可使4 相去极化电流减小，自律性降低。
Ⅲ类：延长动作电位时程药（钾通道阻滞药），如胺碘酮，抑制Kv 通道，可使复极化3相钾离子外流减少，明显延长动作电位时程，使有效不应期延长，消除折返。
Ⅳ类：钙通道阻滞药，如维拉帕米、地尔硫卓，阻断钙通道，使动作电位4相钙离子内流减少，慢反应细胞自律性降低，可用来治疗室上性心律失常。
——以上四类主要治疗快速型心律失常
目前无论哪种抗心律失常药物均有一定的致心律失常作用。Ⅰ类药物可因阻断钠通道减慢传导而诱发折返；Ⅲ类药物因延长动作电位时程而诱发长QT综合症。这引起了人们的重视，寻找新的更安全的治疗方法迫在眉睫。九十年代中期以后，心导管介入技术治疗各类心律失常取得了很大进展，开辟了心律失常治疗的新方向。但介入治疗有一定的适应症范围，故对于多数心律失常患者而言，药物治疗仍是治疗的主要方法或必需的组成部分。由于Ⅰ类药物可因阻断钠通道减慢传导而诱发折返；近年来, 对于抗心律失常药物的研究, 已从Ⅰ 类抗心律失常药转到Ⅲ类抗心律失常药。Ⅲ类抗心律失常药以延长动作电位时程(action potential duration，APD)和有效不应期(effective refractory period，ERP)为特点发挥作用，通过抑制折返激动而有效防治房扑、房颤及室颤，基本不影响传导，对血液动力学无明显影响。
抗心律失常药物致心律失常作用的原因是多方面的，许多学者认为应开辟新思路，寻找新药物。
内向整流钾通道（Inward rectifier potassium channel，IK1)负载电流是心肌最主要的背景外向电流，参与静息电位（Resting potential，RP)的维持和心肌动作电位（Action potential，AP）3期终末的复极（图1）。调节IK1必将影响心肌静息膜电位的稳定和动作电位复极，从而对心肌的兴奋性和心律失常的发生产生深刻影响。
IK1理应成为抗心律失常药物作用的新靶点。但是目前临床应用的抗心律失常药物没有一种是以IK1作为主要靶点的。其原因来自两个方面：一是迄今没有一种高选择性的IK1阻断剂或激动剂。缺乏必要的药理学工具药，极大限制了IK1与心律失常关系的研究；二是尽管许多实验研究证实阻断IK1可有效抑制折返性心律失常的发生，但阻断IK1带来的风险也是显而易见的。从理论上讲，IK1被抑制将使膜去极化，细胞的兴奋性和自律性增高，易化延迟后除极（DAD）等触发活动的发生；IK1的抑制使膜电阻增大，放大了跨膜电流引起的膜电位波动，造成膜电位的不稳定；抑制IK1还可延长动作电位时程（APD），引发长QT综合征。诸多研究已证实IK1的功能获得或功能缺失参与了心律失常及病理性重构的发生发展。但是既往由于缺乏高选择性IK1阻断剂或激动剂，以及利用转基因或基因敲除方法改变心肌IK1表达，远非生理状态，使得相关研究存在极大限制性。2012年，吴博威教授课题组首次报道了一个IK1选择性激动剂—zacopride，通过激动IK1可使静息电位负值增大（超极化），动作电位时程轻度缩短（Liu QH, Li XL, Xu YW, Lin YY, Cao JM, Wu BW. A Novel Discovery of IK1 Channel Agonist: Zacopride Selectively Enhances IK1 Current and SuppressesTriggered Arrhythmias in the Rat. J Cardiovasc Pharmacol, 2012, 59(1): 37–48.）。 而对其他影响动作电位的主要离子通道或交换体如Ito、ICa-L、INa、INa/Ca、Ipump、IK（豚鼠）等均无显著影响。利用这个工具药，IK1在心律失常中的作用逐渐得到阐释。该课题组在大鼠急性心肌缺血模型和心梗后慢性心律失常模型上首次证实适度激动IK1通道对缺血性心律失常有抑制作用。
缺血性心律失常是临床更常见、危害性更大的心律失常。各种类型的心肌缺血均可诱发心律失常，以室性心律失常为主，是引起心肌梗死患者早期死亡的主要原因；在急性心肌梗死幸存的人群中，50% 以上仍死于致命的室性心律失常。而心肌缺血和心肌梗死时发生的心律失常也被证实与IK1的下降有关。有研究显示大鼠慢性动物心肌梗死模型的心肌IK1减小20%；而慢性心梗的家兔非梗死区心室肌细胞IK1也明显减小；Pinto 等证实，狗心肌缺血区心内膜下普肯野纤维静息电位减小，是由于IK1减小造成的。Kiesecker等在人的心肌细胞证明，内皮素可显著抑制IK1，此作用是内皮素致缺血性心律失常的重要机制。心肌缺血时IK1下调及/或功能减弱使静息钾电导下降，导致静息电位（负值）减小和兴奋传导减慢，易形成折返；钾电导下降还会引发膜电位不稳定和异常自律活动增加，这些都是心肌缺血（包括急性和慢性）时发生心律失常的重要原因。
但目前为止，也只有zacopride这样一个IK1特异性激动剂被公开报道。建立激动心肌IK1与抗心律失常理论关系仍显薄弱，迫切需要找到新的IK1特异性激动剂。现在，我们发现了一种药物，其具有和zacopride相类似的效果。
发明内容
目前无论哪种抗心律失常药物均有一定的致心律失常作用，而本药物作为IK1激动剂，可能具有抗心律失常作用，可以成为一条有效、安全治疗的新途径。对此，本发明人通过对扎考比利的深入分析，通过组学大数据的药物重定位平台的大量研究，发现了呋喃妥因能够有效的作为IK1特异性激动剂，其具有和zacopride相类似的效果。进一步研究结果显示呋喃妥因（Nitrofurantoi）对动作电位的作用特征符合IK1激动剂的特点，因而能够有望开发一种新的药物。
故本发明提供呋喃妥因在制备治疗心律失常药物中的应用。
其中，所述的药物为胶囊、微囊、脂质体、颗粒体、注射液、片剂，或口服液。
优选地，其呋喃妥因使用剂量为0.018--1.8mg/kg。
进一步的，将呋喃妥因与钠通道阻滞药、β受体阻断药、钾通道阻滞药、钙通道阻滞药联合使用。
本发明首次发现呋喃妥因能够有效的作为IK1特异性激动剂，其具有和zacopride相类似的效果，可以作为制备抗心律失常作用的药物，因而提供了一条有效、安全治疗的新途径。
附图说明
图1 参与形成心肌动作电位（AP）的离子通道及相应时相。
图2 呋喃妥因（Nitrofurantoi）可增大静息电位，缩短动作电位时程。
具体实施方式
下面结合具体实施方式进一步阐述本发明。
实施例一：呋喃妥因的筛选
IK1选择性激动剂—扎考比利（zacopride），通过激动IK1可使静息电位负值增大（超极化），动作电位时程轻度缩短。基于组学大数据的药物重定位平台寻求扎考比利作用相似物，利用人直结肠癌细胞系HCT116，经zacopride孵育24h，行转录组测序（RNA-seq），对两组“Ctl_VS_Za_1(对照组VS zacopride 1 μM)和Ctl_VS_Za_40(对照组VS zacopride 40μM)”的差异表达分析结果进行校验，差异结果一致后，分别得到两组差异基因：Ctl_VS_Za_1组差异基因226个，上调187个，下调39个；Ctl_VS_Za_40组差异基因302个，上调250个，下调52个。将两组差异表达基因导入基于转录组数据的药物重定位平台，最终得到呋喃妥因可能与zacopride具有相似作用。
实施例二：检测呋喃妥因对左心室肌细胞静息电位和动作电位影响。
（1）实验方法：膜片钳全细胞记录，电压钳模式记录膜电流，电流钳模式记录膜电位
（2）观测指标：药物作用前后大鼠心室肌静息电位（RMP）、动作电位幅度（APA）和时程（APD50，APD90） 的变化。
由于IK1是决定静息电位（RMP）水平和动作电位（AP）3期终末复极的主要离子流，本发明人首先观察抗生素呋喃妥因（Nitrofurantoi）对左心室肌细胞静息电位和动作电位影响。
（1）采用胶原酶法急性分离大鼠左室心肌细胞
选用健康成年雄性SD大鼠（体重220~250 g），腹腔注射戊巴比妥钠（40 mg/kg）麻醉，颈动脉放血后开胸迅速取出心脏，将其置于无钙台氏液（4ºC预冷，100%氧气饱和）中，快速修剪后将心脏悬挂在Langendorff灌流装置灌流（灌流液全程充以100%氧气，逆行经主动脉灌至冠状动脉））。先灌流8~10 min（无钙台氏液），后换液（胶原酶液）循环灌流15~20 min。灌流条件：室温和灌流液始终保持37ºC恒温，灌流压80 cmH2O。将配好的KB液分为A、B两部分，观测心脏肌组织变大、变软，冠脉血管边缘不清时迅速剪下左心室，用A液快速冲洗，后将其置于A液中，眼科剪剪至2-3mm3小块，用玻璃吸管（尖端圆润，以免损伤肌细胞）轻轻吹打3~5min。将A液过滤（150 μm孔径的滤网），滤液置于B液中，静置2~3小时（室温）后进行实验。
（2）全细胞膜片钳记录
将静置于高钾KB液中的细胞吹散，梯度复钙（终浓度1.8mmol/L），根据细胞密度吸取2~3滴细胞悬液滴入含台式液约1 ml的细胞池，静置10 min，待细胞充分贴壁后，用流速2 ml/min的台氏液灌流。相应电极内液充灌于玻璃电极，入液后电阻约2~5 MΩ。选取表面光滑、横纹清晰、无自主收缩且与周围细胞无重叠的杆状心肌细胞作为实验细胞。负压抽吸形成高阻（>1 GΩ）封接，进行电极电容补偿，待其稳定2~3 min后给予负压破膜，电流钳模式下，分别观测不同浓度药物对大鼠心室肌细胞RMP和AP的影响。
（3）如图2所示，呋喃妥因（Nitrofurantoi）可剂量依赖性增大静息电位，并缩短动作电位终末复极时间 （APD90）。
本发明研究结果显示呋喃妥因（Nitrofurantoi）对动作电位的作用特征符合IK1激动剂的特点。适度增强IK1，进而增大或恢复静息电位，对抗缺血性心律失常的机制在于： ①静息电位负值增大，可反转病理因素导致的膜去极化，降低细胞的兴奋性，②增加钠通道的可利用度，提高缺血区心肌的传导速度，有利于消除折返[19]；③增大膜电导，减小膜电流变化引起的膜电位异常波动，增加膜的电稳定性；④适当缩短动作电位时程（APD），有助于防止早后除极（EAD）和由此引起的触发性心律失常。
因而应用呋喃妥因（Nitrofurantoi）可能作为新型抗心律失常药具有抗室性心律失常的作用。应当理解的是，对本领域普通技术人员来说，可以根据上述说明加以改进或变换，而所有这些改进和变换都应属于本发明所附权利要求的保护范围。
Claims (4)
1.呋喃妥因在制备治疗心律失常药物中的应用。
2.如权利要求1所述的应用，其特征在于：所述的药物为胶囊、微囊、脂质体、颗粒体、注射液、片剂，或口服液。
3.如权利要求1所述的应用，其特征在于：其呋喃妥因使用剂量为0.018-1.8mg/kg。
4.如权利要求1所述的应用，其特征在于：将呋喃妥因与钠通道阻滞药、β受体阻断药、钾通道阻滞药、钙通道阻滞药联合使用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810946685.7A CN110840886A (zh) | 2018-08-20 | 2018-08-20 | 抗生素呋喃妥因（Nitrofurantoi）可作为新型抗心律失常药物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810946685.7A CN110840886A (zh) | 2018-08-20 | 2018-08-20 | 抗生素呋喃妥因（Nitrofurantoi）可作为新型抗心律失常药物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110840886A true CN110840886A (zh) | 2020-02-28 |
Family
ID=69595004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810946685.7A Pending CN110840886A (zh) | 2018-08-20 | 2018-08-20 | 抗生素呋喃妥因（Nitrofurantoi）可作为新型抗心律失常药物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110840886A (zh) |
-
2018
- 2018-08-20 CN CN201810946685.7A patent/CN110840886A/zh active Pending
Non-Patent Citations (1)
| Title |
|---|
| O.O.NOVIKOV等: "Prooxidant Effects of Nitrofurantoin", 《BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Napolitano et al. | Torsade de pointes: mechanisms and management | |
| Collura et al. | Left cardiac sympathetic denervation for the treatment of long QT syndrome and catecholaminergic polymorphic ventricular tachycardia using video-assisted thoracic surgery | |
| Sicouri et al. | Cellular basis for the electrocardiographic and arrhythmic manifestations of Timothy syndrome: effects of ranolazine | |
| Ogletree et al. | Prostaglandin-induced preservation of the ischemic myocardium. | |
| Yang et al. | Sevoflurane postconditioning improves myocardial mitochondrial respiratory function and reduces myocardial ischemia-reperfusion injury by up-regulating HIF-1 | |
| Bolli et al. | Factors that determine the occurrence of arrhythmias during acute myocardial ischemia | |
| Bogus et al. | 2-phenyl-1-(3-pyrrolidin-1-il-propyl)-1 H-indole hydrochloride (SS-68): Antiarrhythmic and cardioprotective activity and its molecular mechanisms of action (Part I) | |
| Thomas et al. | Arteriovenous potassium changes and ventricular arrhythmias after coronary artery occlusion | |
| Dubey et al. | Magnesium, myocardial ischaemia and arrhythmias: The role of magnesium in myocardial infarction | |
| CN110840886A (zh) | 抗生素呋喃妥因（Nitrofurantoi）可作为新型抗心律失常药物 | |
| CN110917195A (zh) | 肌松剂阿库氯铵（Alcuronium chloride）可作为抗心律失常药物 | |
| Bianco et al. | Technetium-99m (Sn2+) pyrophosphate in ischemic and infarcted dog myocardium in early stages of acute coronary occlusion: histochemical and tissue-counting comparisons | |
| Xing et al. | The effects of allitridi and amiodarone on the conduction system and reverse use-dependence in the isolated hearts of rats with myocardial infarction | |
| CN110840888A (zh) | 驱虫剂四咪唑可作为新型抗心律失常药物 | |
| CN110840891A (zh) | 降压药潘必定（Pempidine）可作为新型抗心律失常药物 | |
| Kabell et al. | Regional myocardial blood flow and ventricular arrhythmias following one-stage and two-stage coronary artery occlusion in anesthetized dogs | |
| Slusher et al. | Effect of Midbrain Lesions on Ovulation and Adrenal Response to Stress in Female Rats. | |
| Anselmi et al. | Ventricular aneurysms in acute experimental Chagas' myocardiopathy | |
| CN115364115A (zh) | 红景天苷在制备干预缺血再灌注心律失常的药物中的应用 | |
| CN111228277B (zh) | 20(R)-25-羟基-达玛烷型-3β,12β,20-三醇的药物用途 | |
| Ma et al. | Sevoflurane Improves Ventricular Conduction by Exosomes Derived from Rat Cardiac Fibroblasts After Hypothermic Global Ischemia-Reperfusion Injury | |
| CN116392480A (zh) | 褪黑激素在制备治疗心律失常药物中的应用 | |
| Ribeiro et al. | A method for demonstrating the efficacy of interventions designed to limit infarct size following coronary occlusion: beneficial effect of hyaluronidase | |
| Watanabe et al. | Effects of the antianginal drug Trapidil on atrioventricular conduction disturbances during acute myocardial ischemia | |
| Liu et al. | Disassociation between left ventricular mechanical and electrical properties in ischemic rat heart after G-CSF treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200228 |